Page last updated: 2024-12-08

u-104

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SLC-0111: a carbonic anhydrase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID310360
CHEMBL ID1615281
SCHEMBL ID672955
MeSH IDM0590076

Synonyms (61)

Synonym
AKOS001123930
U104 ,
4-{[(4''-fluorophenyl)carbamoyl]amino}benzenesulfonamide
bdbm50334354
4-(3-(4-fluorophenyl)ureido)benzenesulfonamide
nsc-213841
nsc213841
1-(4-fluorophenyl)-3-(4-sulfamoylphenyl)urea
4-(((4-fluoroanilino)carbonyl)amino)benzenesulfonamide
U-104 ,
4-{[(4-fluorophenyl)carbamoyl]amino}benzenesulfonamide
wwz ,
slc-0111
4-{[(4'-fluorophenyl)carbamoyl]amino}benzenesulfonamide
slc0111
CHEMBL1615281 ,
S2866
178606-66-1
c13h12fn3o3s
4-[[[(4-fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide
SCHEMBL672955
3N4B
CS-4495
YJQZNWPYLCNRLP-UHFFFAOYSA-N
u 104
4-[[[(4-fluorophenyl)amino]carbonyl]amino]-benzesulfonamide
HY-13513
AC-32932
J-690246
(3?,5?)-3,14,17-trihydroxycard-20(22)-enolide
u-104;nsc213841;mst104
EX-A904
mst-104
FT-0699833
HMS3651H21
mfcd00159265
AS-66547
3-(4-fluorophenyl)-1-(4-sulfamoylphenyl)urea
u-104, >=98% (hplc)
NCGC00379154-03
SW220124-1
Q27467365
Z55286485
gtpl10149
4-fluorophenylureido-benzenesulfonamide
compound 7 [pmid: 21361354]
A14959
carbonic anhydrase ix/xii inhibitor ii(u-104)
SB19580
HMS3872E13
CCG-267573
BCP14895
nsc 213841
4-[[[(4-fluorophenyl)amino]carbonyl]amino]benzenesulfonamide
A881383
benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]carbonyl]amino]-
anm9dbl9jt ,
4-((((4-fluorophenyl)amino)carbonyl)amino)benzenesulfonamide
unii-anm9dbl9jt
benzenesulfonamide, 4-((((4-fluorophenyl)amino)carbonyl)amino)-
EN300-6472708

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"No dose-limiting toxicities were reported and patients dosed at ≤1000 mg exhibited fewer drug-related AEs ≥ grade 3 and fewer AEs such as nausea and vomiting, compared with the 2000-mg cohort."( A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.
Bedard, PL; Chia, S; Chu, Q; Dedhar, S; Lyle, M; McDonald, PC; Renouf, DJ; Singh, M; Supuran, CT; Tang, L; Zhang, Z, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GVesicular stomatitis virusPotency11.98770.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency21.31740.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency11.98770.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09600.09600.09600.0960AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09600.09600.09600.0960AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09600.09600.09600.0960AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09600.09600.09600.0960AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.09600.09600.09600.0960AID977610
Carbonic anhydrase 12Homo sapiens (human)Ki0.00450.00021.10439.9000AID1243107; AID1275631; AID1278564; AID1410858; AID1449746; AID1519746; AID1564417; AID1581515; AID1585353; AID1603061; AID1649854; AID1753389; AID1766625; AID1784931; AID1818407; AID1821398; AID1859986; AID587002
Carbonic anhydrase 1Homo sapiens (human)Ki5.08000.00001.372610.0000AID1243104; AID1275628; AID1304442; AID1379911; AID1410855; AID1449743; AID1453627; AID1564414; AID1581510; AID1585350; AID1603058; AID1649850; AID1753386; AID1766622; AID1784928; AID1818404; AID1821395; AID1859983; AID586999
Carbonic anhydrase 2Homo sapiens (human)Ki0.83660.00000.72369.9200AID1243105; AID1275629; AID1304443; AID1379912; AID1410856; AID1449744; AID1453628; AID1564415; AID1581511; AID1585351; AID1603059; AID1649851; AID1731020; AID1753387; AID1766623; AID1784929; AID1818405; AID1821396; AID1859984; AID551577; AID587000
Carbonic anhydrase 4Homo sapiens (human)Ki0.28600.00021.97209.9200AID1379913; AID1581512
Carbonic anhydrase 7Homo sapiens (human)Ki8.55000.00021.37379.9000AID1453629; AID1581513; AID1649852; AID1766624
Carbonic anhydrase Mycobacterium tuberculosis H37RvKi0.05300.01202.72389.1200AID551580
Beta-carbonic anhydrase 1Mycobacterium tuberculosis H37RvKi0.00640.00483.38419.8400AID551579
Carbonic anhydrase 9Homo sapiens (human)Ki0.04310.00010.78749.9000AID1243106; AID1275630; AID1278563; AID1304444; AID1379914; AID1410857; AID1449745; AID1453630; AID1519745; AID1564416; AID1581514; AID1585352; AID1585366; AID1603060; AID1649853; AID1731027; AID1753388; AID1784930; AID1818406; AID1821397; AID1849564; AID1859985; AID587001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (62)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1419412Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 100 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1410857Inhibition of human CA9 assessed as enzyme inhibitor complex formation preincubated for 15 mins and measured for 10 to 100 secs by phenol red dye based stopped-flow CO2 hydrase assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID587000Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 min by CO2 hydration assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID1564416Inhibition of recombinant human CA9 preincubated for 15 mins by phenol red dye-based stopped-flow CO2 hydration assay2019European journal of medicinal chemistry, Nov-01, Volume: 181New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.
AID1585351Inhibition of recombinant human carbonic anhydrase 2 by stopped flow CO2 hydration assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
AID1410856Inhibition of human CA2 assessed as enzyme inhibitor complex formation preincubated for 15 mins and measured for 10 to 100 secs by phenol red dye based stopped-flow CO2 hydrase assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1818406Inhibition of human CA9 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.
AID1766622Inhibition of recombinant human CA1 pre-incubated for 15 mins measured by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.
AID1410855Inhibition of human CA1 assessed as enzyme inhibitor complex formation preincubated for 15 mins and measured for 10 to 100 secs by phenol red dye based stopped-flow CO2 hydrase assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1581518Selectivity index, ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant human carbonic anhydrase 12
AID1603058Inhibition of recombinant human carbonic anhydrase 1 incubated for 15 mins prior to testing measured for 5 to 10 secs by phenol red-based stopped-flow CO2 hydration assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1275631Inhibition of human carbonic anhydrase 12 for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.
AID1753386Inhibition of recombinant human CA1 pre-incubated for 15 mins measured by phenol red dye based stopped flow CO2 hydration assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.
AID1818404Inhibition of human CA1 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.
AID1379927Cytotoxicity against human HT-29 cells assessed as reduction in cell viability at 30 to 300 uM after 48 hrs under hypoxic condition by MTT assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID551577Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydrase assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID1581513Inhibition of recombinant human carbonic anhydrase 7 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1821399Selectivity index, ratio of Ki for inhibition of human CA9 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay to Ki for inhibition of human CA2 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assa2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.
AID1419410Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 100 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1379917Gpx-like activity of the compound assessed as GSH-mediated H2O2 reduction by measuring NADPH consumption measured within 100 secs by UV spectroscopic analysis2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1410865Toxicity in Balb/c mouse xenografted with mouse 4T1 cells at 50 to 100 mg/kg, ip administered as daily dose up to 35 days post tumor inoculation2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1453627Inhibition of recombinant human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
AID1818405Inhibition of human CA2 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.
AID1410860Selectivity index, ratio of Ki for human CA2 to Ki for human CA122018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1649852Inhibition of human CA7 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1410866Antitumor activity against mouse 4T1 cells xenografted in Balb/c mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered as daily dose up to 35 days post tumor inoculation2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1753388Inhibition of recombinant human CA9 pre-incubated for 15 mins measured by phenol red dye based stopped flow CO2 hydration assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.
AID1419411Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 200 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1581517Selectivity index, ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant human carbonic anhydrase 9
AID1821396Inhibition of human CA2 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.
AID1379914Inhibition of recombinant human carbonic anhydrase 9 catalytic domain preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1581514Inhibition of recombinant human carbonic anhydrase 9 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1419425Cytotoxicity against human HT-29 cells assessed as cell viability at 200 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1379915Gpx-like activity of the compound assessed as H2O2 reduction by measuring DTT oxidation measured within 35 mins by 1H-NMR analysis2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1379911Inhibition of recombinant human carbonic anhydrase 1 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1859983Inhibition of human carbonic anhydrase 1 assessed as inhibition constant incubated for 15 mins prior to testing by phenol red based stopped-flow CO2 hydration assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.
AID1449746Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
AID1453630Inhibition of recombinant human carbonic anhydrase-9 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
AID1379912Inhibition of recombinant human carbonic anhydrase 2 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1449743Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
AID587001Inhibition of tumor-associated human carbonic anhydrase 9 preincubated for 15 min by CO2 hydration assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID587002Inhibition of tumor-associated human carbonic anhydrase 12 preincubated for 15 min by CO2 hydration assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID1564414Inhibition of recombinant human CA1 preincubated for 15 mins by phenol red dye-based stopped-flow CO2 hydration assay2019European journal of medicinal chemistry, Nov-01, Volume: 181New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.
AID1649854Inhibition of human CA12 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1419424Cytotoxicity against human HT-29 cells assessed as cell viability at 100 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1419420Cytotoxicity against human HT-29 cells assessed as cell viability at 30 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1419416Cytotoxicity against human PC3 cells assessed as cell viability at 200 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1585352Inhibition of recombinant human carbonic anhydrase 9 by stopped flow CO2 hydration assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
AID1603059Inhibition of recombinant human carbonic anhydrase 2 incubated for 15 mins prior to testing measured for 5 to 10 secs by phenol red-based stopped-flow CO2 hydration assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1784931Inhibition of human CA12 measured after 15 mins by stopped flow carbon dioxide anhydrase assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.
AID1784929Inhibition of human CA2 measured after 15 mins by stopped flow carbon dioxide anhydrase assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.
AID1304442Inhibition of human recombinant CA1 preincubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
AID1243105Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity.
AID1649851Inhibition of human CA2 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1821395Inhibition of human CA1 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.
AID1812660Antischistosomal activity against Schistosoma mansoni Puerto-Rican infected in Swiss Webster mouse assessed as worm burden reduction at 50 mg/kg, ip administered at 42, 44 and 46 hrs post infection and measured after 2 weeks2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structural Insights into
AID1379921Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 30 uM after 48 hrs under normoxic condition by MTT assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1453628Inhibition of recombinant human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
AID1419418Cytotoxicity against human PC3 cells assessed as cell viability at 100 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1766623Inhibition of recombinant human CA2 pre-incubated for 15 mins measured by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.
AID1243104Inhibition of human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity.
AID551580Inhibition of Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv3273 preincubated for 15 mins by stopped-flow CO2 hydrase assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID1419409Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 30 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1603060Inhibition of recombinant human carbonic anhydrase 9 incubated for 15 mins prior to testing measured for 5 to 10 secs by phenol red-based stopped-flow CO2 hydration assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1753387Inhibition of recombinant human CA2 pre-incubated for 15 mins measured by phenol red dye based stopped flow CO2 hydration assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.
AID1784930Inhibition of human CA9 measured after 15 mins by stopped flow carbon dioxide anhydrase assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.
AID1419421Cytotoxicity against human HT-29 cells assessed as cell viability at 100 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1519746Inhibition of recombinant human carbonic anhydrase-12 incubated for 15 mins by stopped flow CO2 hydrase assay2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.
AID1278564Inhibition of recombinant human carbonic anhydrase 12 incubated for 15 mins prior to testing by stopped flow carbon dioxide hydrase assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII.
AID1581510Inhibition of recombinant human carbonic anhydrase 1 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1519745Inhibition of recombinant human carbonic anhydrase-9 incubated for 15 mins by stopped flow CO2 hydrase assay2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.
AID1753389Inhibition of recombinant human CA12 pre-incubated for 15 mins measured by phenol red dye based stopped flow CO2 hydration assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.
AID1275630Inhibition of human carbonic anhydrase 9 for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.
AID551579Inhibition of Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv1284 preincubated for 15 mins by stopped-flow CO2 hydrase assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID1849564Binding affinity to human CA9 assessed as inhibition constant by stopped-flow CO2 hydration assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
AID551578Inhibition of Candida albicans recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydrase assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID1859984Inhibition of human carbonic anhydrase 2 assessed as inhibition constant incubated for 15 mins prior to testing by phenol red based stopped-flow CO2 hydration assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.
AID1603061Inhibition of recombinant human carbonic anhydrase 12 incubated for 15 mins prior to testing measured for 5 to 10 secs by phenol red-based stopped-flow CO2 hydration assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1585353Inhibition of recombinant human carbonic anhydrase 12 by stopped flow CO2 hydration assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
AID586999Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 min by CO2 hydration assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID1419419Cytotoxicity against human PC3 cells assessed as cell viability at 200 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1275629Inhibition of human carbonic anhydrase 2 for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.
AID1419417Cytotoxicity against human PC3 cells assessed as cell viability at 30 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1449745Inhibition of human recombinant carbonic anhydrase 9 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
AID1304444Inhibition of human recombinant CA9 preincubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
AID1766625Inhibition of recombinant human CA12 pre-incubated for 15 mins measured by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.
AID1821398Inhibition of human CA12 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.
AID1821397Inhibition of human CA9 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.
AID1649855Inhibition of human CA14 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1419415Cytotoxicity against human PC3 cells assessed as cell viability at 100 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1859985Inhibition of human carbonic anhydrase 9 assessed as inhibition constant incubated for 15 mins prior to testing by phenol red based stopped-flow CO2 hydration assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.
AID1581512Inhibition of recombinant human carbonic anhydrase 4 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1379926Cytotoxicity against human HT-29 cells assessed as reduction in cell viability at 30 to 300 uM after 48 hrs under normoxic condition by MTT assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1731027Inhibition of human CAH9 catalytic domain expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
AID1859986Inhibition of human carbonic anhydrase 12 assessed as inhibition constant incubated for 15 mins prior to testing by phenol red based stopped-flow CO2 hydration assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.
AID1379920Cytotoxicity against human PC3 cells assessed as reduction in cell viability at 300 uM after 48 hrs under normoxic condition by MTT assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1419422Cytotoxicity against human HT-29 cells assessed as cell viability at 200 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1581515Inhibition of recombinant human carbonic anhydrase 12 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1731020Inhibition of human CAH2 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
AID1812658Selectivity ratio of Ki for inhibition of recombinant human carbonic anhydrase 2 to Ki for inhibition of recombinant Schistosoma manson carbonic anhydrase2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structural Insights into
AID1419408Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 200 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1585366Inhibition of carbonic anhydrase 9 (unknown origin)2019European journal of medicinal chemistry, Jan-15, Volume: 162Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
AID1379913Inhibition of recombinant human carbonic anhydrase 4 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors.
AID1419414Cytotoxicity against human PC3 cells assessed as cell viability at 30 uM after 48 hrs under normoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1453629Inhibition of recombinant human carbonic anhydrase-7 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
AID1243107Inhibition of human carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity.
AID1304443Inhibition of human recombinant CA2 preincubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
AID1812657Inhibition of recombinant Schistosoma manson carbonic anhydrase pre-incubated with enzyme for 15 mins by phenol red dye based stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Structural Insights into
AID1278563Inhibition of recombinant human carbonic anhydrase 9 incubated for 15 mins prior to testing by stopped flow carbon dioxide hydrase assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII.
AID1585350Inhibition of recombinant human carbonic anhydrase 1 by stopped flow CO2 hydration assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
AID1649850Inhibition of human CA1 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1818407Inhibition of human CA12 preincubated for 15 mins by phenol red dye based stopped flow CO2 hydration assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.
AID1581511Inhibition of recombinant human carbonic anhydrase 2 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1410859Selectivity index, ratio of Ki for human CA2 to Ki for human CA92018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1603063Selectivity ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant human carbonic anhydrase 92019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1649853Inhibition of human CA9 preincubated for 15 mins by stopped-flow carbon dioxide hydration assay
AID1564415Inhibition of recombinant human CA2 preincubated for 15 mins by phenol red dye-based stopped-flow CO2 hydration assay2019European journal of medicinal chemistry, Nov-01, Volume: 181New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.
AID1449744Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
AID1603062Selectivity ratio of Ki for recombinant human carbonic anhydrase 1 to Ki for recombinant human carbonic anhydrase 92019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
AID1275628Inhibition of human carbonic anhydrase 1 for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.
AID1419423Cytotoxicity against human HT-29 cells assessed as cell viability at 30 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1784928Inhibition of human CA1 measured after 15 mins by stopped flow carbon dioxide anhydrase assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.
AID1410858Inhibition of human CA12 assessed as enzyme inhibitor complex formation preincubated for 15 mins and measured for 10 to 100 secs by phenol red dye based stopped-flow CO2 hydrase assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
AID1419413Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 30 uM after 48 hrs under hypoxic conditions by MTT assay (Rvb = 100%)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
AID1766624Inhibition of recombinant human CA7 pre-incubated for 15 mins measured by stopped flow CO2 hydration assay2021Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.
AID1564417Inhibition of recombinant human CA12 preincubated for 15 mins by phenol red dye-based stopped-flow CO2 hydration assay2019European journal of medicinal chemistry, Nov-01, Volume: 181New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.
AID1243106Inhibition of human carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Chemical communications (Cambridge, England), Nov-28, Volume: 46, Issue:44
Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's26 (44.83)24.3611
2020's32 (55.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.25 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index6.74 (4.65)
Search Engine Demand Index45.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.72%)5.53%
Reviews2 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (94.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]